Published in Can J Gastroenterol Hepatol on December 01, 2014
Ethnicity matters: A Systematic Review and Meta-Analysis of the Non-Linear Relationship Between Alcohol Consumption and Prevalence and Incidence of Hepatic Steatosis. EBioMedicine (2016) 0.82
Aronia melanocarpa Extract Ameliorates Hepatic Lipid Metabolism through PPARγ2 Downregulation. PLoS One (2017) 0.77
Validation of the Fatty Liver Index for Nonalcoholic Fatty Liver Disease in Middle-Aged and Elderly Chinese. Medicine (Baltimore) (2015) 0.77
Non-invasive Markers of Liver Fibrosis: Adjuncts or Alternatives to Liver Biopsy? Front Pharmacol (2016) 0.76
The involvement of ginseng berry extract in blood flow via regulation of blood coagulation in rats fed a high-fat diet. J Ginseng Res (2016) 0.75
Nonmedicinal interventions in nonalcoholic fatty liver disease. Can J Gastroenterol Hepatol (2015) 0.75
Role of Serum Biomarkers in Early Detection of Non-Alcoholic Steatohepatitis and Fibrosis in West Virginian Children. J Clin Cell Immunol (2016) 0.75
Linking atrial fibrillation with non-alcoholic fatty liver disease: potential common therapeutic targets. Oncotarget (2017) 0.75
Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med (1996) 16.98
Leptin and the regulation of body weight in mammals. Nature (1998) 14.84
Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun (1999) 14.25
Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol (1999) 14.07
Weight-reducing effects of the plasma protein encoded by the obese gene. Science (1995) 13.05
Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol (2000) 9.85
Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature (2003) 9.79
A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem (1995) 9.72
Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc (1980) 8.36
Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology (2001) 8.09
Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature (1997) 7.33
Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation (2000) 6.96
AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem (1996) 6.93
cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun (1996) 5.40
Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology (1994) 5.22
Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology (2003) 4.69
The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol (2005) 4.65
ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab (2002) 4.64
Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis (2001) 4.44
Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology (2008) 4.28
Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet (2002) 3.68
Assessment of non-alcoholic fatty liver disease using serum total cell death and apoptosis markers. Aliment Pharmacol Ther (2012) 3.35
Adiponectin--journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med (2005) 3.29
Adolescent obesity increases significantly in second and third generation U.S. immigrants: the National Longitudinal Study of Adolescent Health. J Nutr (1998) 3.11
The crystal structure of a complement-1q family protein suggests an evolutionary link to tumor necrosis factor. Curr Biol (1998) 3.00
Prospective biopsy-controlled evaluation of cell death biomarkers for prediction of liver fibrosis and nonalcoholic steatohepatitis. Hepatology (2011) 2.49
Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol (2009) 2.42
Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women. Hepatology (2005) 2.41
Leptin: the tale of an obesity gene. Diabetes (1996) 2.37
Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut (2010) 2.20
Regulated expression of the obese gene product (leptin) in white adipose tissue and 3T3-L1 adipocytes. Proc Natl Acad Sci U S A (1995) 2.17
Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology (2012) 2.10
Is alanine aminotransferase level a surrogate biomarker of hepatic apoptosis in nonalcoholic fatty liver disease? Biomark Med (2010) 2.05
Decreased plasma adiponectin concentrations in women with dyslipidemia. J Clin Endocrinol Metab (2002) 2.04
Plasma resistin, adiponectin and leptin levels in lean and obese subjects: correlations with insulin resistance. Eur J Endocrinol (2003) 2.04
The alanine aminotransferase to triglycerides ratio as a marker to identify nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol (2012) 2.03
An apoptosis panel for nonalcoholic steatohepatitis diagnosis. J Hepatol (2011) 1.98
Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology (2000) 1.96
Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology (2013) 1.88
Adiponectin and resistin--new hormones of white adipose tissue. Med Sci Monit (2003) 1.85
Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut (2010) 1.84
A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis. Obes Surg (2011) 1.79
Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis. Hepatology (2013) 1.78
Plasma metabolomic profile in nonalcoholic fatty liver disease. Metabolism (2010) 1.77
Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J Clin Endocrinol Metab (2005) 1.73
Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography. Liver Int (2012) 1.71
The clinical significance of slightly to moderately increased liver transaminase values in asymptomatic patients. Scand J Gastroenterol (1999) 1.69
Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds. Am J Med (2000) 1.67
Fatty liver hepatitis and cirrhosis in obese patients. Am J Med (1979) 1.66
Acid ceramidase overexpression prevents the inhibitory effects of saturated fatty acids on insulin signaling. J Biol Chem (2005) 1.63
Hemodynamic and hormonal effects of human ghrelin in healthy volunteers. Am J Physiol Regul Integr Comp Physiol (2001) 1.61
Ghrelin: discovery of the natural endogenous ligand for the growth hormone secretagogue receptor. Trends Endocrinol Metab (2001) 1.61
CYP2E1 and oxidant stress in alcoholic and non-alcoholic fatty liver disease. J Hepatol (2012) 1.53
Association of plasma visfatin with hepatic and systemic inflammation in nonalcoholic fatty liver disease. Ann Hepatol (2013) 1.50
Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease. J Hepatol (2013) 1.48
Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl (2001) 1.45
Non-alcoholic steatohepatitis: association with obesity and insulin resistance, and influence of weight loss. Diabetes Metab (2000) 1.45
Genetic variations of superoxide dismutase 2 and cytochrome P450 2E1 in non-alcoholic steatohepatitis. Liver Int (2014) 1.40
Plasma ghrelin concentrations are decreased in insulin-resistant obese adults relative to equally obese insulin-sensitive controls. J Clin Endocrinol Metab (2004) 1.37
Serum metabolomics reveals γ-glutamyl dipeptides as biomarkers for discrimination among different forms of liver disease. J Hepatol (2011) 1.30
Idiopathic steatohepatitis in childhood: a multicenter retrospective study. J Pediatr (1995) 1.30
Liquid chromatography-mass spectrometry-based parallel metabolic profiling of human and mouse model serum reveals putative biomarkers associated with the progression of nonalcoholic fatty liver disease. J Proteome Res (2010) 1.29
Liver transplantation: current status and novel approaches to liver replacement. Gastroenterology (2001) 1.28
Increased expression of cytochrome P450 2E1 in nonalcoholic fatty liver disease: mechanisms and pathophysiological role. Clin Res Hepatol Gastroenterol (2011) 1.25
Neuroendocrine and peripheral activities of ghrelin: implications in metabolism and obesity. Eur J Pharmacol (2002) 1.24
Irisin in patients with nonalcoholic fatty liver disease. Metabolism (2013) 1.24
Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease--the role of transient elastography and plasma cytokeratin-18 fragments. Aliment Pharmacol Ther (2013) 1.18
Plasma adiponectin levels in overweight and obese Asians. Obes Res (2002) 1.15
Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Metabolism (2010) 1.15
Obesity-dependent metabolic signatures associated with nonalcoholic fatty liver disease progression. J Proteome Res (2012) 1.14
Serum interleukin 1 receptor antagonist as an independent marker of non-alcoholic steatohepatitis in humans. J Hepatol (2011) 1.14
Leptin--from a signal of adiposity to a hormonal mediator in peripheral tissues. Med Sci Monit (2002) 1.14
Serum levels of CK18 M30 and leptin are useful predictors of steatohepatitis and fibrosis in paediatric NAFLD. J Pediatr Gastroenterol Nutr (2010) 1.13
Role of alcohol metabolism in non-alcoholic steatohepatitis. PLoS One (2010) 1.13
Prevalence and risk factors for the development of nonalcoholic fatty liver disease in a nonobese Chinese population: the Zhejiang Zhenhai Study. Am J Gastroenterol (2013) 1.12
Regulation of ob gene mRNA levels in cultured adipocytes. FEBS Lett (1996) 1.12
Serum ferritin is a discriminant marker for both fibrosis and inflammation in histologically proven non-alcoholic fatty liver disease patients. Liver Int (2011) 1.10
Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers. J Hepatol (2012) 1.07
Serum parameters predict the severity of ultrasonographic findings in non-alcoholic fatty liver disease. Hepatobiliary Pancreat Dis Int (2012) 1.04
Pioglitazone in the treatment of NASH: the role of adiponectin. Aliment Pharmacol Ther (2010) 1.01
Recurrence of nonalcoholic steatohepatitis after liver transplantation. Liver Transpl Surg (1997) 1.00
Increased hepatic expression of dipeptidyl peptidase-4 in non-alcoholic fatty liver disease and its association with insulin resistance and glucose metabolism. Mol Med Rep (2011) 1.00
Risk of fatty infiltration or cirrhosis of the liver in relation to ethanol consumption: a case-control study. Clin Invest Med (1986) 0.99
Liver transplantation for cryptogenic cirrhosis. Liver Transpl Surg (1997) 0.99
Serum proteomic analysis revealed diagnostic value of hemoglobin for nonalcoholic fatty liver disease. J Hepatol (2011) 0.98
Serum progranulin as an independent marker of liver fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease. Dis Markers (2011) 0.97
Serum apoptotic caspase activity in chronic hepatitis C and nonalcoholic Fatty liver disease. J Clin Gastroenterol (2010) 0.97
Combined paediatric NAFLD fibrosis index and transient elastography to predict clinically significant fibrosis in children with fatty liver disease. Liver Int (2012) 0.96
Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: proof of concept and first application in a large population. J Hepatol (2012) 0.95
Genomic aspects of NAFLD pathogenesis. Genomics (2013) 0.95
Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data. PLoS One (2012) 0.94
Serum cytokeratin-18 fragment levels are useful biomarkers for nonalcoholic steatohepatitis in children. Am J Gastroenterol (2013) 0.94
Preliminary evidence of a reduced serum level of fibroblast growth factor 19 in patients with biopsy-proven nonalcoholic fatty liver disease. Clin Biochem (2012) 0.93
Association between insulin resistance and oxidative stress parameters in obese adolescents with non-alcoholic fatty liver disease. J Clin Res Pediatr Endocrinol (2013) 0.93
How adiponectin, leptin, and ghrelin orchestrate together and correlate with the severity of nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol (2012) 0.93
Cytokeratin-18 and hyaluronic acid levels predict liver fibrosis in children with non-alcoholic fatty liver disease. Acta Biochim Pol (2011) 0.93
A proton nuclear magnetic resonance metabonomics approach for biomarker discovery in nonalcoholic fatty liver disease. J Proteome Res (2011) 0.92
Serum adipocyte-specific fatty acid-binding protein is associated with nonalcoholic fatty liver disease in apparently healthy subjects. J Nutr Biochem (2010) 0.90
Soluble CD14 levels reflect liver inflammation in patients with nonalcoholic steatohepatitis. PLoS One (2013) 0.90
Validation of noninvasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in patients with morbid obesity. Eur J Gastroenterol Hepatol (2011) 0.89
Endoscopist-directed administration of propofol: a worldwide safety experience. Gastroenterology (2009) 3.75
Single action potentials and subthreshold electrical events imaged in neurons with a fluorescent protein voltage probe. Neuron (2012) 2.68
Endoscopic, deep mural implantation of Enteryx for the treatment of GERD: 6-month follow-up of a multicenter trial. Am J Gastroenterol (2003) 2.63
The association between alcohol use, alcohol use disorders and tuberculosis (TB). A systematic review. BMC Public Health (2009) 2.39
Temporal dynamics and latency patterns of receptor neuron input to the olfactory bulb. J Neurosci (2006) 2.06
Efficiency of an endoscopy suite in a teaching hospital: delays, prolonged procedures, and hospital waiting times. Gastrointest Endosc (2006) 2.04
Endoscopic implantation of enteryx for treatment of GERD: 12-month results of a prospective, multicenter trial. Am J Gastroenterol (2003) 1.84
A randomized, multicenter study comparing the safety and efficacy of sodium phosphate tablets with 2L polyethylene glycol solution plus bisacodyl tablets for colon cleansing. Am J Gastroenterol (2007) 1.74
Position statement: Nonanesthesiologist administration of propofol for GI endoscopy. Gastroenterology (2009) 1.67
Sightline ColonoSight system for a disposable, power-assisted, non-fiber-optic colonoscopy (with video). Gastrointest Endosc (2008) 1.60
Sedation for gastrointestinal endoscopy: new practices, new economics. Am J Gastroenterol (2005) 1.51
A simple tissue-handling technique performed in the endoscopy suite improves histologic section quality and diagnostic accuracy for serrated polyps. Endoscopy (2013) 1.43
Imaging brain activity with voltage- and calcium-sensitive dyes. Cell Mol Neurobiol (2005) 1.42
Position statement: Nonanesthesiologist administration of propofol for GI endoscopy. Hepatology (2009) 1.41
Inflammatory bowel disease: role of diet, microbiota, life style. Transl Res (2011) 1.37
Interglomerular center-surround inhibition shapes odorant-evoked input to the mouse olfactory bulb in vivo. J Neurophysiol (2005) 1.30
A morphologic analysis of sessile serrated polyps observed during routine colonoscopy (with video). Gastrointest Endosc (2011) 1.22
Position statement: nonanesthesiologist administration of propofol for GI endoscopy. Gastrointest Endosc (2009) 1.17
Synthesis, spectra, delivery and potentiometric responses of new styryl dyes with extended spectral ranges. J Neurosci Methods (2005) 1.16
Correspondence between odorant-evoked patterns of receptor neuron input and intrinsic optical signals in the mouse olfactory bulb. J Neurophysiol (2002) 1.15
Adverse drug reactions induced by valproic acid. Clin Biochem (2013) 1.14
Distributed and concentration-invariant spatial representations of odorants by receptor neuron input to the turtle olfactory bulb. J Neurophysiol (2002) 1.13
Wide-field and two-photon imaging of brain activity with voltage- and calcium-sensitive dyes. Philos Trans R Soc Lond B Biol Sci (2009) 1.12
Genetically encoded fluorescent voltage sensors using the voltage-sensing domain of Nematostella and Danio phosphatases exhibit fast kinetics. J Neurosci Methods (2012) 1.12
Fluorescent protein voltage probes derived from ArcLight that respond to membrane voltage changes with fast kinetics. PLoS One (2013) 1.11
Position statement: Nonanesthesiologist administration of propofol for GI endoscopy. Am J Gastroenterol (2009) 1.08
Octreotide in bronchobiliary fistula management. Ann Thorac Surg (2004) 1.03
Guidelines for safety in the gastrointestinal endoscopy unit. Gastrointest Endosc (2014) 1.03
From personalized medicine to personalized justice: the promises of translational pharmacogenomics in the justice system. Pharmacogenomics (2010) 1.01
Optical monitoring of neural activity using voltage-sensitive dyes. Methods Enzymol (2003) 0.99
The challenge of connecting the dots in the B.R.A.I.N. Neuron (2013) 0.99
Presynaptic inhibition of olfactory receptor neurons in crustaceans. Microsc Res Tech (2002) 0.98
Imaging nervous system activity with voltage-sensitive dyes. Curr Protoc Neurosci (2003) 0.94
Alcohol Consumption, Progression of Disease and Other Comorbidities, and Responses to Antiretroviral Medication in People Living with HIV. AIDS Res Treat (2012) 0.94
HIV-Antiretroviral Therapy Induced Liver, Gastrointestinal, and Pancreatic Injury. Int J Hepatol (2012) 0.93
The Link between Hypersensitivity Syndrome Reaction Development and Human Herpes Virus-6 Reactivation. Int J Hepatol (2012) 0.91
Endoscopic sedation in developing and developed countries. Gut Liver (2008) 0.91
Wide-field and two-photon imaging of brain activity with voltage- and calcium-sensitive dyes. Methods Mol Biol (2009) 0.91
Cutaneous nocardiosis complicating management of Crohn's disease with infliximab and prednisone. CMAJ (2004) 0.90
Safety of anti-tumor necrosis factor therapies in arthritis patients. J Pharm Pharm Sci (2014) 0.90
Hyaluronic acid and wound healing. J Pharm Pharm Sci (2015) 0.89
Single-nucleotide polymorphisms in inflammatory bowel disease. Transl Res (2011) 0.88
Antiepileptic drug-induced hypersensitivity syndrome reactions. Curr Drug Saf (2006) 0.88
Is gastroduodenal biopsy safe in patients receiving aspirin and clopidogrel?: a prospective, randomized study involving 630 biopsies. J Clin Gastroenterol (2011) 0.87
Nutritional and probiotic supplementation in colitis models. Dig Dis Sci (2012) 0.87
Sedation in endoscopic practice. Gastrointest Endosc Clin N Am (2006) 0.87
Odorant specificity of three oscillations and the DC signal in the turtle olfactory bulb. Eur J Neurosci (2003) 0.87
Propofol use under the direction of trained gastroenterologists: an analysis of the medicolegal implications. Am J Gastroenterol (2007) 0.86
The detection of premalignant colon polyps during colonoscopy is stable throughout the workday. Gastrointest Endosc (2011) 0.84
In vitro anti-inflammatory effects of hyaluronic acid in ethanol-induced damage in skin cells. J Pharm Pharm Sci (2011) 0.84
Oscillations in the olfactory bulb carry information about odorant history. J Neurophysiol (2005) 0.84
Ibuprofen-induced hypersensitivity syndrome. Transl Res (2010) 0.83
Metabolome and inflammasome in inflammatory bowel disease. Transl Res (2011) 0.83
Endoscopic sedation of patients with chronic liver disease. Clin Liver Dis (2010) 0.83
Changes in the pathogenesis of alcohol-induced liver disease -- preclinical studies. Exp Mol Pathol (2013) 0.83
Historical Overview and General Methods of Membrane Potential Imaging. Adv Exp Med Biol (2015) 0.82
Optical analysis of circuitry for respiratory rhythm in isolated brainstem of foetal mice. Philos Trans R Soc Lond B Biol Sci (2009) 0.82
Genetic and immune predictors for hypersensitivity syndrome to antiepileptic drugs. Transl Res (2012) 0.82
The changing faces of endoscopic sedation. Expert Rev Gastroenterol Hepatol (2010) 0.81
Hepatotoxicity of Pyrrolizidine Alkaloids. J Pharm Pharm Sci (2015) 0.81
Colorectal polyposis and immune-based therapies. Can J Gastroenterol (2004) 0.80
Is production pressure jeopardizing the quality of colonoscopy? A survey of U.S. endoscopists' practices and perceptions. Gastrointest Endosc (2012) 0.80
Chemotherapies and targeted therapies in advanced hepatocellular carcinoma: from laboratory to clinic. J Gastrointestin Liver Dis (2008) 0.79
Efficacy and safety of platelet inhibitors. J Pharm Pharm Sci (2013) 0.78
Making 1+1=3: improving sedation through drug synergy. Gastrointest Endosc (2011) 0.78
Risk of infections of biological therapies with accent on inflammatory bowel disease. J Pharm Pharm Sci (2014) 0.78
Production pressure in endoscopy: balancing quantity and quality. Gastroenterology (2008) 0.78
One small step for colonoscopy, one giant leap for bowel preparation. Gastrointest Endosc (2012) 0.78
Apoptosis in liver disease. Rom J Gastroenterol (2002) 0.77
Update on colonoscopy preparation, premedication and sedation. Expert Rev Gastroenterol Hepatol (2013) 0.77
Genetically Encoded Protein Sensors of Membrane Potential. Adv Exp Med Biol (2015) 0.77
Colon polyps and cytokines: emerging immunological mechanisms. Rom J Gastroenterol (2003) 0.77
In Vivo Voltage-Sensitive Dye Imaging of Mammalian Cortex Using "Blue" Dyes. Cold Spring Harb Protoc (2015) 0.77
Drug-induced severe adverse reaction enhanced by human herpes virus-6 reactivation. Transl Res (2013) 0.77
Primary prevention of adverse gastroduodenal effects from short-term use of non-steroidal anti-inflammatory drugs by omeprazole 20 mg in healthy subjects: a randomized, double-blind, placebo-controlled study. Dig Dis Sci (2008) 0.76
Human patient simulation and its role in endoscopic sedation training. Gastrointest Endosc Clin N Am (2008) 0.76
Non-Alcoholic Steatohepatitis: Clinical and Translational Research. J Pharm Pharm Sci (2016) 0.76
Now single spines: monitoring neuronal membrane potential with submicron and submillisecond resolution. J Physiol (2010) 0.75
Nonmedicinal interventions in nonalcoholic fatty liver disease. Can J Gastroenterol Hepatol (2015) 0.75
Sedation and polyp detection. Dig Dis Sci (2010) 0.75
Redefining quality in endoscopic sedation. Dig Dis Sci (2010) 0.75
Osteopontin biomarker in inflammatory bowel disease, animal models and target for drug discovery. Dig Dis Sci (2012) 0.75
Oral sodium phosphate and renal function. Arch Intern Med (2008) 0.75
Israel-Gaza conflict. Lancet (2009) 0.75
Re: Disappearance of Crohn's ulcers in the terminal ileum after thalidomide therapy. Can J Gastroenterol 2004; 18(2): 101-104. Can J Gastroenterol (2004) 0.75
Safety of celecoxib in individuals allergic to sulfonamide: a pilot study. Drug Saf (2003) 0.75
The role of the endoscopy nurse or assistant in endoscopic sedation. Gastrointest Endosc Clin N Am (2008) 0.75
Valproic acid derivatives signal for apoptosis and repair in vitro. Clin Biochem (2013) 0.75
Tumor necrosis factor alpha as a noninvasive marker of liver inflammation in patients with viral hepatitis C. Am Clin Lab (2002) 0.75
Does it matter what day of the week you have your colonoscopy? Gastrointest Endosc (2012) 0.75
Voltage-Sensitive Dye Imaging of Population Signals in Brain Slices. Cold Spring Harb Protoc (2015) 0.75
Mechanism of Impila (Callilepis laureola)-induced cytotoxicity in Hep G2 cells. Clin Biochem (2002) 0.75